Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Regen Biopharma, Inc. (OTC: RGBP).

Full DD Report for RGBP

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.00360.00310.00390.0033,416,088
2018-12-130.00420.003380.0050.003314,434,369
2018-12-120.00550.005170.00550.0045615,789
2018-12-110.00680.0050.00680.00482,252,507
2018-12-100.00690.006880.0080.00443,352,051

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14993,7363,416,08829.0899Cover
2018-12-132,014,77414,434,36913.9582Cover
2018-12-12284,295615,78946.1676Short
2018-12-11937,8112,252,50741.6341Short
2018-12-101,322,1903,352,05139.4442Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RGBP.


About Regen Biopharma, Inc. (OTC: RGBP)

Logo for Regen Biopharma, Inc. (OTC: RGBP)

Regen is focused on identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre clinical and Phase I/II clinical trials. Currently the Company is developing products treating blood disorders using small molecules and gene silencing DiffronC , treating cancer with immunotherapy dCellVax , modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches BORIS , and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients HemaXellerate .

 

 

 

Current Management

  • David Koos / CEO
    • David Koos is the Founder, Chairman amp CEO of Regen BioPharma Inc. Dr. Koos has over years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or coauthored numerous peer reviewed journal articles primarily on biotechnology related subjects.
  • Todd Caven / CFO
    • Todd S. Caven is an accomplished executive with years of experience in corporate finance, taxation, mergers amp acquisitions, corporate valuations and financing activities for various types of transactions. In March of , Mr. Caven cofounded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States. Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
  • Dr. Harry M. Lander / CSO, President
    • Dr.Lander received an MBA in Finance from The New York University Stern School of Business in New York City in and a Ph.D. in Biochemistry from the Cornell University Graduate School of Medical Sciences. Dr. Lander has also earned a Bachelor of Science in Biochemistry and a Bachelor of Science in Chemistry from State University of New York at Stony Brook. Prior to accepting the office of President at Regen, Dr. Lander served as Research ChiefAdministration at Sidra Medical and Research Center, a new women and children s hospital expected to open in established to provide care to Qatari and Middle East residents based on the North American academic medical center model. His duties at the Medical and Research Center included assisting in the development of financial, operational , and compliance infrastructures for the Center as well as assisting in developing the Center s scientific strategy through a year strategic plan
  • David Koos / Chairman
    • David Koos is the Founder, Chairman amp CEO of Regen BioPharma Inc. Dr. Koos has over years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or coauthored numerous peer reviewed journal articles primarily on biotechnology related subjects.

Current Share Structure

  • Market Cap: $5,473,026 - 03/21/2018
  • Authorized: 500,000,000 - 01/04/2017
  • Issue and Outstanding: 149,536,219 - 02/21/2018
  • Float: 82,317,059 - 01/04/2017

 


Recent Filings from (OTC: RGBP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: February, 21 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: February, 20 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: January, 05 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: December, 28 2017

 

 


Daily Technical Chart for (OTC: RGBP)

Daily Technical Chart for (OTC: RGBP)


Stay tuned for daily updates and more on (OTC: RGBP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RGBP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RGBP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RGBP and does not buy, sell, or trade any shares of RGBP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/